Kyowa Kirin stock

4151 · TSE · JPY

Compare Kyowa Kirin
¥2,600.50Change from previous close: +0.60%Absolute change: +¥15.50

Close · November 16, 2026

Price history

+4.06% over the period

1 year: from ¥2,499.00 (November 17, 2025) to ¥2,600.50 (November 16, 2026), +4.06%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026¥2,600.50
October 30, 2026¥2,464.00
September 30, 2026¥2,280.00
August 31, 2026¥2,628.00
July 31, 2026¥2,554.50
June 30, 2026¥2,587.00
May 29, 2026¥2,505.00
April 30, 2026¥2,362.00
March 31, 2026¥2,578.00
February 27, 2026¥2,885.00
January 30, 2026¥2,504.50
December 30, 2025¥2,527.00
November 28, 2025¥2,630.50
November 17, 2025¥2,499.00

At a glance

TickerLandia's take on Kyowa Kirin

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥2,109.00
52-wk high¥2,912.00

−10.70% from the 52-week high

Analysts · 11 analysts

Average target¥2,263.64−12.95% vs. price

Buy 1 · Hold 4 · Sell 6 · Sell

TickerLandia Fingerprint: Kyowa Kirin

Compared with similar companies: very high financial strength.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Kyowa Kirin is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Kyowa Kirin's P/E today is 20.3, below the median of its last 10 fiscal years (29.1; between 15.7 and 47.4 from 2016 to 2025). Kyowa Kirin's P/E (trailing 12 months): 16.6, −41% against the median of a group of 11 similar companies (28.4).

P/E compared with its history

Compared with 11 similar companies

Kyowa Kirin's metrics compared with similar companies
MetricKyowa KirinPosition in the groupBand
P/E (trailing 12 months)16.6Low
Forward P/E18.6Middle
Operating margin21.8%Middle
ROE9.8%Low
Debt/equity0.03Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Kyowa Kirin. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥121.32B

Latest quarter · Q3 2026

Net income

¥21.06B

Latest quarter · Q3 2026

Quarterly net margin

17.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥1.35T
P/E
16.6
EPS
¥155.37
Volume
1.14M
Daily trading
€25.52M
Dividend yield
2.58%

How Kyowa Kirin is changing

All results
  • Revenue grew 9.3% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 96% of net income

  • Revenue has grown for 6 fiscal years in a row

Returns

Kyowa Kirin returns with dividends

¥1,000 invested in Kyowa Kirin 5 years ago, on November 16, 2021, would be worth ¥797 today with dividends reinvested: −20.27% in total, −4.43% per year. On price alone it would be ¥716 (−28.36%).

PeriodKyowa KirinNikkei 225¥1,000 becomes
1 month+11.04%−6.39%¥1,110
6 months+9.73%−0.42%¥1,097
Year to date+2.91%+21.48%¥1,029
1 year+6.81%+21.52%¥1,068
3 years+16.45%+82.95%¥1,164
5 years−20.27%+105.15%¥797
10 years+86.27%+242.35%¥1,863

Over the last 6 months it has done better than 39% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment

The chart in detail

Kyowa Kirin: technical analysis

Kyowa Kirin shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 38.2% below its all-time closing high (¥4,210.00, September 24, 2021).

Trend
No clear trend
RSI (14 sessions)
64
Between 30 and 70
vs 200-session average
+5.16%

Support and resistance

Price areas where Kyowa Kirin has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance¥2,711.33+4.26%3 touches, last on July 29, 2026
  2. Resistance¥2,665.90+2.51%5 touches, last on November 5, 2026
  3. Last price¥2,600.50
  4. Support¥2,591.00−0.37%5 touches, last on July 14, 2026
  5. Support¥2,514.13−3.32%4 touches, last on August 18, 2026
  6. Support¥2,454.50−5.61%4 touches, last on August 4, 2026

Volatility and risk

Over the last year it has moved little with the Nikkei 225.

Beta (1 year) vs Nikkei 225
0.18
Volatility (60 sessions, annualised)
39.5%
Largest fall in the last year
−24.99%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Kyowa Kirin: seasonality

Average monthly price change over 37 years

+1.8%Jan+2.0%Feb+0.3%Mar+1.8%Apr+0.2%May+0.6%Jun+1.0%Jul−0.5%Aug+0.1%Sep−0.2%Oct−0.4%Nov−1.5%Dec

Over the last 37 years, the strongest month for Kyowa Kirin has been February: +2.01% on average, positive in 19 years out of 37. The weakest has been December: −1.54% on average, positive in 12 years out of 36. November, the current month, has been positive in 19 years out of 36 (−0.41% on average).

Show chart data
MonthAverageMedianPositive years
January+1.76%−1.22%16 of 36
February+2.01%+0.60%19 of 37
March+0.33%+1.00%21 of 37
April+1.77%+3.33%26 of 37
May+0.22%−0.30%17 of 37
June+0.61%+0.52%20 of 37
July+0.97%+2.62%21 of 37
August−0.45%0.00%18 of 37
September+0.06%+0.42%19 of 37
October−0.22%−0.63%17 of 37
November−0.41%+0.76%19 of 36
December−1.54%−2.20%12 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Kyowa Kirin and its competitors

Kyowa Kirin sells pharmaceuticals across Japan, the Americas, Europe and Asia, and in other international markets, and its development pipeline spans several therapeutic areas. Its marketed products include Ziftomenib, an oral menin inhibitor for adult relapsed or refractory acute myeloid leukemia with an NPM1 mutation, and Lumicef for palmoplantar pustulosis. Among its late-stage candidates are rocatinlimab for atopic dermatitis and prurigo nodularis, and infigratinib for achondroplasia, both in Phase III trials, alongside programs in ophthalmology, rare metabolic disorders and oncology.

Headquarters
Chiyoda, Japan
Employees
5,161
Founded
1949
Chief executive
Abdul Hafeez Mullick
Kyowa Kirin and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Kyowa Kirin4151$8.46B21.8%16.6+9.73%
Eisai4523$9.14B6.7%33.3+11.79%
CiplaCIPLA$11.93B13.0%38.8−2.63%
Zhejiang NHU002001$12.3B33.8%10.9−21.99%
Sumitomo Pharma4506$5.69B-0.4%19.2+18.08%
Zydus LifesciencesZYDUSLIFE$12.59B17.2%28.4+17.82%

Same industry or related industries, similar size. Compare Kyowa Kirin with its competitors · Full profile